Swiss Infrastructure Stock News

SWX:NESN
SWX:NESNFood

How Investors May Respond To Nestlé (SWX:NESN) Q1 Sales Dip Amid Efficiency Drive And Portfolio Shift

Nestlé reported past first-quarter 2026 group sales of CHF 21,317 million, down from CHF 22,601 million a year earlier, while organic growth and volumes improved despite an infant formula recall and currency headwinds. At the same time, the company accelerated portfolio streamlining and cost-saving efforts, including European job cuts and potential further ice cream divestments, highlighting a sharper focus on efficiency and core categories like coffee, pet care and nutrition. We’ll now...
SWX:NOVN
SWX:NOVNPharmaceuticals

Novartis Regulatory Wins Raise Questions On Growth And Valuation Gap

Novartis received a positive opinion from the European Medicines Agency for its gene therapy Itvisma for spinal muscular atrophy in older children and adults. The World Health Organization prequalified Novartis's pediatric antimalarial Coartem Baby, supporting broader access for infants in malaria endemic regions. For investors tracking Novartis, ticker SWX:NOVN, these regulatory milestones sit alongside a current share price of CHF113.7. The stock shows a 4.8% return year to date and a...
SWX:UBSG
SWX:UBSGCapital Markets

UBS Faces Swiss Capital Dispute And Reassesses Growth Versus Resilience

UBS Group (SWX:UBSG) is challenging new Swiss capital rules that it describes as extreme and harmful for the Swiss economy. The Swiss government has finalized capital adequacy requirements that would add significant capital demands on UBS, including 100% capital backing for foreign units at the parent level. UBS has publicly opposed these measures, arguing they are not aligned with international standards and could affect the bank's global operations. UBS is one of the largest global wealth...
SWX:AMRZ
SWX:AMRZBasic Materials

Is There An Opportunity In Amrize (SWX:AMRZ) After Recent Steady Share Performance

If you are wondering whether Amrize at around CHF44.64 is priced attractively or not, the key question is how its current share price compares with its underlying business value. Recently, the stock has been relatively steady, with a 1.1% return over the last 30 days and a 3.0% decline over the last 7 days. This may reflect shifting views on its near term prospects and risk. Recent news flow on Amrize has focused more on maintaining investor visibility than on any single transformational...
SWX:NESN
SWX:NESNFood

A Look At Nestlé (SWX:NESN) Valuation As Turnaround Plan Gains Traction After First Quarter Beat

Nestlé (SWX:NESN) is back in focus after first quarter sales exceeded expectations, supported by 3.5% organic growth across categories like coffee and snacks, while management reaffirmed its full year outlook despite currency and recall headwinds. See our latest analysis for Nestlé. The recent first quarter beat and portfolio reshaping, including the planned Blue Bottle Coffee sale and potential ice cream exit, have supported a 90 day share price return of 12.01%. This comes even as the 1...
SWX:COPN
SWX:COPNPharmaceuticals

Cosmo Pharmaceuticals (SWX:COPN) Valuation Reassessed After Strong Phase III Alopecia Results And Regulatory Plans

Cosmo (SWX:COPN) is back in focus after reporting 12 month Phase III results for its Clascoterone 5% topical solution in male androgenetic alopecia, highlighting long term safety, ongoing efficacy and preparation for global regulatory filings. See our latest analysis for Cosmo. The latest clinical update comes after a mixed period in the market, with a 23.6% 1 month share price return and a 16.99% 3 month decline. Meanwhile, the 1 year total shareholder return sits at 111.93%, suggesting...
SWX:ROP
SWX:ROPPharmaceuticals

Is Roche Holding (SWX:ROP) Pricing Reflect Its CHF 773 DCF Estimate After 27.7% Year Gain?

Wondering if Roche Holding at around CHF324.90 is offering fair value or if the price is running ahead of the story? This article focuses squarely on what that share price may or may not reflect. Over the past week the stock returned 3.6% and over the last month 6.2%. The 1 year return stands at 27.7%, and the year to date move is close to flat at a 0.2% decline. Recent news flow around Roche Holding has kept attention on the stock, from ongoing discussion of its position in global...
SWX:ABBN
SWX:ABBNElectrical

ABB’s HiPerGuard UPS Ties AI Data Center Demand To Record Orders

ABB launched its HiPerGuard 34.5kV medium voltage UPS for AI data centers, enabling direct-to-grid power connections. The system is microgrid ready and is the first in its class to receive UL 9540 certification for safety and performance. ABB reported record order intake and cash flow alongside this product launch, highlighting strong operating momentum. ABB (SWX:ABBN) is drawing attention with this data center focused UPS launch while its shares trade around CHF78.1. The stock has...
SWX:PGHN
SWX:PGHNCapital Markets

3 European Growth Stocks To Watch With Over 10% Insider Ownership

As European markets experience a positive upswing, highlighted by gains in major indices like Germany’s DAX and France’s CAC 40, investors are closely monitoring the region's economic outlook amid geopolitical developments. In this environment, growth companies with substantial insider ownership can be particularly appealing as they often signal strong confidence from those closest to the business operations.
SWX:SCHN
SWX:SCHNMachinery

Schindler Holding (SWX:SCHN) Margin Improvement To 9.3% Tests Earnings Resilience Narrative

Schindler Holding (SWX:SCHN) has opened Q1 2026 earnings season with a clean set of headline numbers, coming off Q4 2025 revenue of CHF 2.8b and basic EPS of CHF 2.46, supported by trailing 12 month revenue of CHF 11.0b and EPS of CHF 9.48 as earnings grew 6.8% over the past year. Over recent quarters the company has seen revenue move within a CHF 2.7b to CHF 2.9b range while quarterly EPS has held between CHF 2.16 and CHF 2.46, which points to a business that is leaning on steady...
SWX:NOVN
SWX:NOVNPharmaceuticals

Is It Too Late To Consider Novartis (SWX:NOVN) After A 30% One-Year Jump?

Some investors may be wondering whether Novartis at around CHF116 per share is still good value, or if most of the opportunity is already reflected in the price. The stock has had a 1% decline over the past week and past month, while posting returns of 7.2% year to date and 30.2% over the last year. This may catch the eye of investors weighing reward against risk. Recent headlines have highlighted Novartis as a large, established player in global pharmaceuticals. This keeps it on the radar...
SWX:UBSG
SWX:UBSGCapital Markets

Is UBS Group (SWX:UBSG) Still Attractive After Its Strong One Year Share Price Rally?

Wondering whether UBS Group at around CHF33.54 is still good value or starting to look stretched? This overview is built to help you frame that question clearly. The stock has had mixed recent performance, with a 0.9% decline over the last 7 days, a 14.0% gain over the last 30 days, a 12.1% decline year to date, and a 42.1% return over the last year, alongside multi year returns of 102.9% over 3 years and 172.7% over 5 years. Recent coverage of UBS Group has focused on its position as a...
SWX:PMN
SWX:PMNElectrical

3 European Dividend Stocks Yielding Up To 4.4%

As European markets experience a positive upswing, with the STOXX Europe 600 Index rising by 1.91% amid easing geopolitical tensions and steady corporate earnings, investors are increasingly looking to dividend stocks as a reliable income source. In this context, selecting dividend stocks that offer stable yields can be particularly appealing for those seeking consistent returns in an environment where economic forecasts remain cautious.
SWX:ROP
SWX:ROPPharmaceuticals

Roche Holding (SWX:ROP) Valuation Check As Key Immunology And Neurology Milestones Draw Attention

Roche Holding (SWX:ROP) is back in focus after regulators accepted a key filing for Gazyva in systemic lupus erythematosus, along with new Phase III data for fenebrutinib and Enspryng in multiple sclerosis and MOGAD. See our latest analysis for Roche Holding. Despite a series of positive trial readouts and the FDA accepting the Gazyva filing, Roche Holding’s CHF313.1 share price has a 30 day share price return of 3.03%, a 90 day share price return of 10%, and a 1 year total shareholder return...
SWX:ABBN
SWX:ABBNElectrical

ABB (SWX:ABBN) Valuation Check After Q1 Beat And AI Data Center Order Surge

Q1 results and outlook shift ABB (SWX:ABBN) drew fresh investor attention after reporting first quarter results and raising its full year revenue expectations, supported by strong electrification orders tied to AI related data center demand. The company reported first quarter revenue of US$8,734 million and net income of US$1,324 million, with electrification orders up 44% and comparable orders up 24%, including very strong order growth from data center projects. See our latest analysis for...
SWX:ROG
SWX:ROGPharmaceuticals

Roche Holding (SWX:ROG) Valuation After FDA Lupus Update And New C4 Therapeutics Oncology Collaboration

Roche Holding (SWX:ROG) has drawn fresh investor attention after the FDA accepted its supplemental Biologics License Application for Gazyva/Gazyvaro in systemic lupus erythematosus and the company expanded its oncology research collaboration with C4 Therapeutics. See our latest analysis for Roche Holding. The recent FDA sBLA acceptance for Gazyva/Gazyvaro in systemic lupus erythematosus and the new degrader antibody collaboration with C4 Therapeutics come after a mixed stretch for the shares,...